cyclopentane has been researched along with Testicular Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andò, S; Avena, P; Bartucci, M; Casaburi, I; Chimento, A; Dattilo, R; Patrizii, M; Pezzi, V; Sirianni, R | 1 |
| Andrews, NC; Aust, JB; Lawton, RL; Schroeder, JM | 1 |
1 trial(s) available for cyclopentane and Testicular Neoplasms
| Article | Year |
|---|---|
Clinical note. Phase II study of 1-aminocyclopentanecarboxylic acid (NSC-1026) in patients with cancer.
Topics: Amino Acids; Clinical Trials as Topic; Colonic Neoplasms; Cyclopentanes; Evaluation Studies as Topic; Feeding and Eating Disorders; Head and Neck Neoplasms; Humans; Leiomyosarcoma; Male; Neoplasms; Rectal Neoplasms; Sarcoma; Testicular Neoplasms; Valine; Vomiting | 1970 |
1 other study(ies) available for cyclopentane and Testicular Neoplasms
| Article | Year |
|---|---|
Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Cell Line, Tumor; Cell Nucleus Shape; Cell Proliferation; Cyclopentanes; DNA Damage; Estradiol; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Leydig Cell Tumor; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Quinolines; Rats; Receptors, G-Protein-Coupled; Testicular Neoplasms; Testis; Xenograft Model Antitumor Assays | 2013 |